The goal of the new SCI Community Partnership Seed Grant Program is to foster cancer prevention and control efforts that are community driven by partnering Stanford faculty and staff with community partners to jointly develop projects. Projects should form new or strengthen existing partnerships and implement and evaluate new ideas or interventions. Project focus should be on addressing the cancer burden of medically underserved populations including those in rural areas or racial/ethnic minorities in the SCI catchment area. The long term sustainability of projects and partnerships is critical. Full program announcement >>

Example project categories include (but are not limited to):

• Impact of COVID-19 relating to cancer 
• Surveys to evaluate community need
• Pilot testing for access to care, early detection/screening, vaccination programs
• Development of online tools/resources that support prevention and cancer control
• Educational resources promoting diversity in clinical trials
• Cancer prevention and control educational events in the community
• Community convening to discuss implementation of cancer prevention initiatives

Eligibility: Stanford faculty, clinical educators and UHA physicians, clinical instructors, instructors, graduate students, post-doctoral scholars (clinical and non-clinical) and staff are eligible to apply. All proposed projects must have an identified community partner as a co-collaborator on the project. Projects involving multidisciplinary teams are highly encouraged.

Please contact the Stanford Cancer Institute if you need assistance in identifying a community partner or Stanford faculty/staff member. Please send all inquiries to: sci-coeprogram@stanford.edu or through our technical assistance portal.

Total Funds Available (Up to $25,000 Per Award): Requests can be made to fund small projects ($1,000 - $5,000) or to fund a pilot grant of up to $25,000. Funds will be awarded for a one-year grant period. Awards will be granted for the period from January 1, 2021 through December 31, 2021 and are encouraged to be completed in that timeframe. No-cost extension of funds remaining at the end of the period will be considered on a case by case basis if progress has been demonstrated. Upon completion, grantees will be required to submit a written summary report about their awarded projects. Grantees have an additional option to present their project outcomes to Stanford affiliates.

SCI Community Outreach and Engagement Proposal: Please complete the fillable pdf application and submit your proposal to sci-coeprogram@stanford.edu

Deadline: All proposals must be submitted by 3 pm PST on Friday October 30, 2020

Pilot Grant Process and Timeline:

1. RFP released August 10, 2020

2. RFP due on October 30, 2020

3. Project Review Committee Meet – Week of November 9, 2020

4. Funding announcements made on November 20, 2020

5. Awards granted on January 1, 2021 – December 31, 2021

The Stanford Cancer Institute’s (SCI) mission is to reduce cancer mortality and improve cancer care through comprehensive programs of cancer research, prevention, treatment, education and outreach. To achieve its mission, the leadership and members relentlessly pursue multiple strategic aims which include fostering interdisciplinary basic cancer research, translating scientific discovery into clinical research and optimal patient care, developing improved approaches to the prevention, early detection, precise diagnosis and effective treatment of cancer, and improving the cancer patient experience by using research to develop and validate innovative initiatives in patient-centered care.

In keeping with its core mission, the SCI offers Innovation Awards to support projects focused on the acceleration of basic, translational, clinical and population-based cancer research, and projects focused on specific types of cancer, such as pancreatic, breast and gynecologic cancers. This award cycle, we encourage proposals related to the Priority Cancers-Breast, Pancreatic, Liver, Lung, and Lymphoma.

AWARD CATEGORIES:

• Stanford Cancer Institute Nodal Grant Awards ($50,000) 
• Stanford Cancer Institute Innovation Awards ($50,000)
  • Single PI
  • Multi PI collaboration leading to multi PI peer-reviewed funding
• Stanford Cancer Institute Pancreatic Cancer Innovation Awards ($50,000)
• Stanford Women's Cancer Center Innovation Awards ($50,000)

AWARD CATEGORY DESCRIPTIONS:

Stanford Cancer Institute Nodal Grant Awards (SCI-NGA) - $50,000 
The SCI offers a funding mechanism, which aims to catalyze the planning and execution of multi-PI grants from the National Cancer Institute, including R01s, P01s and SPOREs. The funds are intended to be used to obtain proof of concept data and support planning activities.   

Stanford Cancer Institute Cancer Innovation Award (SCI-IA) - $50,000
The SCI offers awards to support projects focused on the acceleration of basic, translational, clinical and population-based cancer research and collaborations leading to multi PI peer-reviewed funding.

Stanford Cancer Institute Pancreatic Cancer Innovation Award (SCI-PCIA) - $50,000
The SCI offers awards leading to a greater understanding of pancreatic cancer, with the ultimate goal of improving the prevention or treatment of pancreatic cancer.

Stanford Women’s Cancer Center Innovation Award (SWCC-IA) - $50,000
With support from the fundraising efforts of Under One Umbrella, the SCI and the Stanford Women’s Cancer Center offer awards for research projects related to women’s cancers.

TIMELINE (Anticipated / Exact dates TBD)

RFA Announced:  September 15 2020
Proposal submission deadline: November 2, 2020   
Notification of Selection: January, 2021
Funding Period:  March 1, 2021 – February 28, 2022

PROGRAM PRIORITIES 

• Bold and creative research projects
• Research related to health disparities
• Multi-disciplinary collaboration, including collaborations involving Stanford faculty beyond the School of Medicine or inter-programmatic collaborations across the seven SCI research programs
• Potential to lead (or is already leading) to an investigator-initiated clinical trial
• Plans for submission of an external peer reviewed (preferably NCI) application

ELIGIBILITY: 

Faculty members of the SCI or of the Stanford University community with PI Status.

***If the PI is not a SCI member, the submission must include a letter of support from a sponsoring SCI member, who would also be a project collaborator.

IMPORTANT: If you are interested in submitting more than 1 project, please contact Gayle White at gwhite5@stanford.edu prior to proposal submission of either proposal. Seedfunding.stanford.edu will only allow 1 proposal per PI (sunet ID), per funding opportunity.

Apply here >>

Stanford Medicine and the Rambam Healthcare Campus of Israel have launched a broad, multi-faceted health sciences Collaboration. The Collaboration provides up to $50,000 for one year (with the option to renew for one year) to fund the exchange of faculty and trainees between the two institutions.
 
Funding will be available beginning January 2021. 
 
CRITERIA
Eligibility:

• Academic and clinical faculty, postdoctoral students, medical students, residents, and other licensed health professionals (including, but not limited to, nurses, advanced practice nurses, physicians, etc.) from both institutions may apply.
• For applicants requesting clinical privileges at either institution, necessary licensing credentials must be obtained prior to release of the money.  If not accomplished at the start of the grant, the matter will undergo review by the Steering Committee.

 
Applications: Grant requests for academic exchange/fellowships should include a description of the project and desired mentor(s) in the application. It is recommended to have a host institution mentor (primary) and a home institution mentor (secondary).
 
Areas of interest to the Collaboration include, but are not limited to

• Device innovation
• Cancer discovery and care delivery research
• COVID/pandemic and disaster preparedness
• Drug discovery through SPARK collaboration
• Cardiovascular stem cell research
• Big data analytics

 
INSTRUCTIONS

• Applicants need to complete the Information Form and supplemental application materials for approval.
• Applications are accepted on a rolling basis until December 1, 2020
• Submit completed applications to both Kelsey Sobomehin (Kelsey.Sobomehin@stanford.edu) and Netta Glebotzki (n_glebotzki@rambam.health.gov.il).
• Applications will be reviewed by a joint steering committee and will be considered for funding based on collaboration priorities and available funds.
• Applicants must complete all of the steps listed below for an application to be considered complete. Incomplete applications will not be reviewed.

NIH NCI Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional) (RFA-CA-19-034)

Purpose
The purpose of this Funding Opportunity Announcement (FOA) is to support the planning and development of translational research programs focused upon cancer health disparities research. The P20 grants supported by this FOA are expected to expand into comprehensive translational research programs focused upon cancer health disparities and ultimately compete for P50 awards under the umbrella of the National Cancer Institute (NCI) "Specialized Programs of Research Excellence (SPOREs)".

Each P20 Program proposed must include the following components:

The research supported through the P20 Program must be translational in nature and must focus upon knowledge of human biology with a translational human endpoint proposed. The proposed research theme for the P20 Program must be focused on addressing disparities in cancer incidence, prevalence, mortality, survivorship, and/or burden of cancer, or related health conditions, that are well documented among racial/ethnic minority populations. Projects may focus on a wide range of research areas including prevention, early detection, diagnosis, treatment, epidemiology and/or cancer control, and are expected to have clear translational potential to advance research findings to applications relevant for clinical practice and/or healthcare settings.

1. Research Program (at least two translational research projects are required);
2. Administrative Core;
3. Shared Resource Facility (Biospecimen/Pathology Core is required); and
4. Developmental Research Program.

Amount of funding:  Applicants may request a maximum of $800,000 direct costs per year.

Letter of Intent Due Dates: 30 days prior to the application due date

Application Due Dates: June 19, 2019, October 18, 2019, June 19, 2020, and October 18, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement .

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Earliest Start Dates: April 2020; July 2020; April 2021; July 2021 

RFA and Guidelines: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-034.html

This Request for Applications is associated with the Partnership for Accelerating Cancer Therapies (PACT), a project associated with the Beau Biden Cancer Moonshot ™ Initiative that is intended to accelerate cancer research.The overall goal for this Request for Applications (RFA) is to solicit clinical trials to partner with the PACT initiative to provide biospecimens for exploratory deep immunoprofiling analysis, employing this standardized set of biomarker assays. More information >>

The PACT partnership will consider supporting the deployment of the selected standardized biomarker assays in a broad range of IO trials. The group is encouraging trials from any cancer type that is comparing effects of immune therapy or immune therapy in combinations with another therapy. Examples of IO considered include, but are not limited to:

• Immune Checkpoint Inhibitors (ICIs)
• Other immune modulators
• Immunotherapy in combination immune modulators, targeted agents or chemotherapy/radiotherapy
• Adoptive Cell Therapy
• Immune vaccine therapies

Applications will be reviewed on a rolling basis and in order of submission. All applications must be received prior to January 31, 2022.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to develop, adapt, and test individual-, community- or multilevel interventions to address modifiable risk factors for cancer in rural populations. Applications should focus on primary prevention and assess and address one or more of the social and behavioral risk factors that contribute to cancer disparities in rural populations: tobacco use; diet, physical activity and weight; alcohol use; UV exposure; and HPV vaccination. Applications should also assess and address myriad social determinants of health, cultural factors, and health care and technology access barriers that may contribute to rural cancer disparities. This FOA also encourages implementation science research, to incorporate efficacious cancer control interventions in a coordinated way, into broader, sustainable health programs that are designed to reach rural populations and allow local customization and adaptation.

Deadline: March 15, 2021; January 18, 2022

Read more or apply >>

The National Cancer Institute (NCI) and Cancer Research UK (CRUK) has announced a new partnership, the Cancer Grand Challenges program. Cancer Grand Challenges seeks novel ideas by multidisciplinary research teams from around the world that offer the potential to advance bold cancer research and improve outcomes for people affected by cancer. Full program announcement >>

Today, we are excited to share the nine challenges that have been released as part of this effort. These challenges were identified through international workshops and open calls for ideas from the cancer research community and people affected by cancer. Of these, the most compelling ideas were evaluated by experts in cancer research and their recommendations were provided to CRUK. As funding partners, NCI and CRUK made the final decisions on the Cancer Grand Challenges. More information about these challenges can be found on the Cancer Grand Challenges page on cancer.gov. The nine challenges are:

• Understand how cells and tissues maintain “normal” phenotypes while harboring oncogenic mutations and how they transition to become a tumor 
• Systematically deliver macromolecules to intracellular targets for therapeutic benefit in cancer 
• Understand and exploit senescence to improve cancer treatment 
• Determine the potential benefits and risks of e-cigarette use 
• Determine how inflammation causes cancer 
• Develop novel therapies to target unique features in solid tumors in children  
• Understand the biology of extrachromosomal DNA (ecDNA) generation and action and develop approaches to target these mechanisms in cancer 
• Identify and target dormant cancer cells 
• Understand and reverse cachexia and declining performance status in cancer patients 

Expressions of interest are now being accepted through April 22, 2021.

Apply here >>

On October 30, 2017 the National Cancer Institute is pleased to announce the release of 17 new Cancer Moonshot funding opportunities. As you know, efforts supported through the Cancer Moonshot aim to accelerate cancer research, making more therapies available to patients and improving the ability to prevent cancer and detect it the earliest stage possible.

Following receipt of the Blue Ribbon Panel report, NCI identified funding opportunity announcements (FOAs) from within its extensive research portfolio that address the goals of the Cancer Moonshot. These opportunities mark the beginning of a growing Cancer Moonshot portfolio which will continue to expand given the authorization of the 21st Century Cures Act to fund the Beau Biden Cancer Moonshot with $1.8 billion over 7 years. While the FOAs listed below highlight research initiatives that align with the efforts of the Cancer Moonshot, they may be supported with existing funds or with the 21st Century Cures funding.

On October 30, 2017 the National Cancer Institute is pleased to announce the release of 17 new Cancer Moonshot funding opportunities. As you know, efforts supported through the Cancer Moonshot aim to accelerate cancer research, making more therapies available to patients and improving the ability to prevent cancer and detect it the earliest stage possible. Learn more about these opportunities here.

Cancer Moonshot - UPDATED Funding Opportunities link